Please login to the form below

Not currently logged in
Email:
Password:

Frances Heller joins BMS senior management

Takes up business development role and will report to Lamberto Andreotti

Bristol-Myers Squibb has appointed Frances Heller as senior vice president, business development.

Reporting to the pharma company's CEO Lamberto Andreotti, she will also sit on the BMS senior management team.

Heller comes to BMS from Exelixis, a San Francisco-based genomics drug discovery company, where she was executive vice president of business development.

Prior to that she served as head of strategic alliances at Novartis and before that as corporate and intellectual property counsel for Celera Genomics.

“With broad experience across both the biotech and pharmaceutical industries, I believe Fran will be an important addition to my diverse management team and to the company,” said Andreotti.

“In addition, her scientific, business and legal background, as well as her experience across therapeutic areas, will help Bristol-Myers Squibb continue to execute its strategy of finding external innovation that complements our own internal R&D pipeline and helps us bring important new medicines to patients.”

2nd October 2012

From: PME

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

We are GCI Health, one of the world’s largest specialist healthcare communications agencies with global hubs in London and New...

Latest intelligence

blog-icon_build_your_argumentation.png
Build your e-detailing argumentation
We’ve written a number of posts recently giving insights into the Anthill method for structuring e-detailing & CLM presentations. To help you overview, we’ve put these argumentation posts together....
Growing influence of pharmacists in the sale of Rx and OTC medicines
Find out how the changes within pharmacy have affected their influence over the sales of RX and OTC medicines in this whitepaper....
Drivers of 2014′s Soaring Drug Approvals
The FDA & EMA approved a chart-topping number of new drugs in 2014. Read more in our White Paper about the responsibility this growing approval success will put on future...